As expected, the percentage of tumor-infiltrating CD8+ T cells among whole CD45+ population was significantly elevated in mice treated with combination therapy as compared with mice with monotherapy (Supplementary Fig. 3A). This evidence concerns the gene PTPRC and neoplasm.